[Evaluation of a semi-automated test for quantification of von Willebrand multimers].

Évaluation d’un test semi-automatisé de quantification des multimères du facteur von Willebrand.
Acquired von Willebrand Syndrome Mechanical Circulatory Device electrophoresis von Willebrand Factor von Willebrand factor multimers

Journal

Annales de biologie clinique
ISSN: 1950-6112
Titre abrégé: Ann Biol Clin (Paris)
Pays: France
ID NLM: 2984690R

Informations de publication

Date de publication:
01 Aug 2024
Historique:
medline: 31 8 2024
pubmed: 31 8 2024
entrez: 30 8 2024
Statut: aheadofprint

Résumé

The assessment of von Willebrand factor (VWF) multimer distribution, particularly following the implantation of circulatory support devices, is a crucial parameter in hemostasis. Our study aimed to evaluate the semi-automated quantification of VWF multimers using the Sebia Hydrasys analyzer. Our analysis focused on quantifying high molecular weight, intermediate weight, and low molecular weight VWF multimers. Electrophoretic migration was performed using the Hydrasys 2 scan, and interpretation was carried out using densitometric analysis with the Phoresis software. The Hydrasys scan 2 successfully separated all the expected VWF multimer profiles based on the type of von Willebrand disease. The analysis revealed that in patients with circulatory support devices, elevated levels of plasma VWF rendered multimer migration unanalyzable using the methodology recommended by the manufacturer. Therefore, adjustment to a 100 % VWF antigenic level improved gel precision. We also suggest using as a standardized control the Cryocheck™ plasma, and have established reference values. Overall, this semi-automated, standardized, and optimized VWF multimer analysis system allows for an effective assessment of the VWF multimeric profile.

Identifiants

pubmed: 39210589
pii: abc.2024.1903
doi: 10.1684/abc.2024.1903
doi:

Types de publication

English Abstract Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

0

Auteurs

Christophe Peronino (C)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France.

Nadia Rivet (N)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

Nathalie Itzhar-Baikian (N)

AP-HP.Nord, Université Paris Cité, Hôpital Lariboisière, Service d'hématologie biologique, F-75010 Paris, France, Université Paris Cité, EA3518, Institut de recherche Saint-Louis, Paris, France.

Aurélien Philippe (A)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

Bérangère S Joly (BS)

AP-HP.Nord, Université Paris Cité, Hôpital Lariboisière, Service d'hématologie biologique, F-75010 Paris, France, Université Paris Cité, EA3518, Institut de recherche Saint-Louis, Paris, France.

Joseph Roux de Bezieux (JR)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France.

Anne-Céline Martin (AC)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service de chirurgie cardiaque- UMICS, F-75015 Paris, France.

Sophie Luneau (S)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

Agnès Veyradier (A)

AP-HP.Nord, Université Paris Cité, Hôpital Lariboisière, Service d'hématologie biologique, F-75010 Paris, France, Université Paris Cité, EA3518, Institut de recherche Saint-Louis, Paris, France.

Pascale Gaussem (P)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

Nicolas Gendron (N)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

David M Smadja (DM)

Université Paris Cité, Innovative Thérapies in Haemostasis, INSERM UMR-S1140, F-75006 Paris, France, AP-HP, Hôpital européen Georges Pompidou, Service d'Hématologie biologique, F-75015 Paris, France.

Classifications MeSH